Use of quantitative clinical pharmacology to improve early clinical development success in neurodegenerative diseases

ABSTRACT Introduction: The success rate of pharmaceutical Research & Development (R&D) is much lower compared to other industries such as micro-electronics or aeronautics with the probability of a successful clinical development to approval in central nervous system (CNS) disorders hovering in the single digits (7%). Areas covered: Inspired by adjacent engineering-based industries, we argue that quantitative modeling in CNS R&D might improve success rates. We will focus on quantitative techniques in early clinical development, such as PharmacoKinetic–PharmacoDynamic modeling, clinical trial simulation, model-based meta-analysis and the mechanism-based physiology-based pharmacokinetic modeling, and quantitative systems pharmacology. Expert commentary: Mechanism-based computer modeling rely less on existing clinical datasets, therefore can better generalize than Big Data analytics, including prospectively and quantitatively predicting the clinical outcome of new drugs. More specifically, exhaustive post-hoc analysis of failed trials using individual virtual human trial simulation could illuminate underlying causes such as lack of sufficient functional target engagement, negative pharmacodynamic interactions with comedications and genotypes, and mismatched patient population. These insights are beyond the capacity of artificial intelligence (AI) methods as they are many more possible combinations than subjects. Unlike ‘black box’ approaches in AI, mechanism-based platforms are transparent and based on biologically sound assumptions that can be interrogated.

[1]  M. Danhof,et al.  Extending a Systems Model of the APP Pathway: Separation of β- and γ-Secretase Sequential Cleavage Steps of APP , 2018, The Journal of Pharmacology and Experimental Therapeutics.

[2]  Anne-Christin Hauschild,et al.  GWAS-based machine learning approach to predict duloxetine response in major depressive disorder. , 2018, Journal of psychiatric research.

[3]  O. Demin,et al.  A mathematical model of multisite phosphorylation of tau protein , 2018, PloS one.

[4]  Hugo Geerts,et al.  Impact of amyloid-beta changes on cognitive outcomes in Alzheimer’s disease: analysis of clinical trials using a quantitative systems pharmacology model , 2018, Alzheimer's Research & Therapy.

[5]  Mohammed H. Cherkaoui-Rbati,et al.  A quantitative systems pharmacology approach, incorporating a novel liver model, for predicting pharmacokinetic drug-drug interactions , 2017, PloS one.

[6]  Paul B Watkins,et al.  The role of quantitative systems pharmacology modeling in the prediction and explanation of idiosyncratic drug-induced liver injury. , 2017, Drug metabolism and pharmacokinetics.

[7]  S. Subramaniam,et al.  Computational Modeling of Competitive Metabolism between ω3- and ω6-Polyunsaturated Fatty Acids in Inflammatory Macrophages. , 2016, The journal of physical chemistry. B.

[8]  P. Snyder,et al.  Disruption of cholinergic neurotransmission exacerbates Aβ-related cognitive impairment in preclinical Alzheimer's disease , 2015, Neurobiology of Aging.

[9]  Hugo Geerts,et al.  Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology , 2015, Front. Pharmacol..

[10]  David J Klinke,et al.  Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study , 2015, Journal of Immunotherapy for Cancer.

[11]  S. Potkin,et al.  Understanding responder neurobiology in schizophrenia using a quantitative systems pharmacology model: Application to iloperidone , 2015, Journal of psychopharmacology.

[12]  D Polhamus,et al.  The future is now: Model‐based clinical trial design for Alzheimer's disease , 2015, Clinical pharmacology and therapeutics.

[13]  José Pinheiro,et al.  Model‐based clinical drug development in the past, present and future: a commentary , 2015, British journal of clinical pharmacology.

[14]  Alan C. Evans,et al.  Epidemic Spreading Model to Characterize Misfolded Proteins Propagation in Aging and Associated Neurodegenerative Disorders , 2014, PLoS Comput. Biol..

[15]  H. Geerts,et al.  A computer-based quantitative systems pharmacology model of negative symptoms in schizophrenia: exploring glycine modulation of excitation-inhibition balance , 2014, Front. Pharmacol..

[16]  J. Cummings,et al.  Alzheimer’s disease drug-development pipeline: few candidates, frequent failures , 2014, Alzheimer's Research & Therapy.

[17]  M. Ostland,et al.  Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. , 2014, JAMA psychiatry.

[18]  H Geerts,et al.  Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model , 2014, CPT: pharmacometrics & systems pharmacology.

[19]  R Gieschke,et al.  Modeling Alzheimer's Disease Progression Using Disease Onset Time and Disease Trajectory Concepts Applied to CDR-SOB Scores From ADNI , 2013, CPT: pharmacometrics & systems pharmacology.

[20]  Hugo Geerts,et al.  Systems pharmacology modeling in neuroscience: Prediction and outcome of PF-04995274, a 5-HT4 partial agonist, in a clinical scopolamine impairment trial , 2013 .

[21]  Hugo Geerts,et al.  Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development , 2013, Journal of Pharmacokinetics and Pharmacodynamics.

[22]  S. Visser,et al.  Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data , 2013, European Journal of Clinical Pharmacology.

[23]  Hugo Geerts,et al.  Blinded Prospective Evaluation of Computer-Based Mechanistic Schizophrenia Disease Model for Predicting Drug Response , 2012, PloS one.

[24]  H Geerts,et al.  Has the Time Come for Predictive Computer Modeling in CNS Drug Discovery and Development? , 2012, CPT: pharmacometrics & systems pharmacology.

[25]  William F. C. Baaré,et al.  5-HTTLPR status predictive of neocortical 5-HT4 binding assessed with [11C]SB207145 PET in humans , 2012, NeuroImage.

[26]  Klaus Romero,et al.  Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis , 2012, Journal of Pharmacokinetics and Pharmacodynamics.

[27]  M. Gibbs,et al.  Model‐Based Meta‐Analysis for Comparative Efficacy and Safety: Application in Drug Development and Beyond , 2011, Clinical pharmacology and therapeutics.

[28]  H. Geerts.  Of Mice and Men , 2009, CNS drugs.

[29]  M. Polymeropoulos,et al.  Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study , 2009, Molecular Psychiatry.

[30]  Jianhua Shi,et al.  PKA modulates GSK‐3β‐ and cdk5‐catalyzed phosphorylation of tau in site‐ and kinase‐specific manners , 2006, FEBS letters.

[31]  Wayne Ewy,et al.  Application of Clinical Trial Simulation to Compare Proof-of-Concept Study Designs for Drugs with a Slow Onset of Effect; An Example in Alzheimer's Disease , 2006, Pharmaceutical Research.

[32]  C. Gong,et al.  Hyperphosphorylation of tau and protein phosphatases in Alzheimer disease. , 2006, Panminerva medica.

[33]  L. Edelstein-Keshet,et al.  Exploring the formation of Alzheimer's disease senile plaques in silico. , 2002, Journal of theoretical biology.

[34]  M. Hines,et al.  The NEURON Simulation Environment , 1997, Neural Computation.

[35]  R. Peck.  Strategies in Selecting an Agent for Clinical Trials , 1997, Annals of the New York Academy of Sciences.

[36]  W. Tsai,et al.  A functional decline model for prevalent cohort data. , 1996, Statistics in medicine.

[37]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[38]  Bischoff Kb,et al.  Some fundamental considerations of the applications of pharmacokinetics to cancer chemotherapy. , 1975 .

[39]  N H Holford,et al.  Drug treatment effects on disease progression. , 2001, Annual review of pharmacology and toxicology.

[40]  N H Holford,et al.  Simulation of clinical trials. , 2000, Annual review of pharmacology and toxicology.

[41]  K. Bischoff.  Some fundamental considerations of the applications of pharmacokinetics to cancer chemotherapy. , 1975, Cancer chemotherapy reports.